Inflammatory Bowel Disease (IBD) is a lifelong illness requiring close management. Prompt disease recognition and tight control of disease activity reduces disease morbidity and improves outcomes1. Endoscopy with histologic examination is the gold standard for assessing “deep remission2.” However, frequent endoscopic evaluation is not always feasible or cost effective. Fecal Calprotectin (FC), a paradigm shifting biomarker, is both sensitive and specific for histologic inflammation in IBD2. However, the efficacy of this test rests on patient’s willingness to handle and submit stool samples.